Evaluation of the Effect of Prescribed Drugs in the Treatment of Patients with Coronavirus 2019 (COVID-19), At Least 14 Days Follow-Up

Abstract

Background:Coronavirus Respiratory Syndromeis as a cause of severe respiratory infections in human, it is a global threat that can cause respiratory infections such as the common cold, severe acute respiratory syndrome and Middle East respiratory syndrome. The aim of this study was to evaluate the effect of prescribed drugs on the treatment of patients with coronavirus disease 2019 (COVID-19), at least 14 days of follow-up who their infection was confirmed to be positive. In this study, a checklist contains information like demographic ,Duration of hospitalization , Cough, Fever, Olfactory-taste disorders, chest X-ray, records were collected from patients and, were analyzed using descriptive statistical methods. The study was performed on 100 Covid-19 patients , with a mean age of 53.49 years. Patients had the initial diagnostic symptoms of Cough, Fever, 84% of whom showed sore throat , and 85% had body pain. 71% of hospitalized patients developed symptoms of Olfactory-taste disorders. Also, the mean length of hospitalization was achieved to be 8.26±1.01, which decreased according to the type of treatment. In patients who took Remdesivir, Favipiravir, Hydroxychloroquine alone, the mean length of hospitalization was 7.12± 1.11, in patients who took the compound drugs Kaletra , hydroxychloroquine /azithromycin, the average time for hospitalization was declined to 4.22± 0.02 while the plasma and interferon takers’ groups it was 3.00± 0.01 and 2.5 ± 0.09 days, respectively. The study shows that there is a significant relationship between the type of drug used and the shorter course of the disease, which needs further study for better results